{"id":771222,"date":"2023-07-20T08:50:49","date_gmt":"2023-07-20T12:50:49","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/clearside-biomedicals-suprachoroidal-injection-platform-to-be-featured-at-upcoming-asrs-and-ois-scientific-meetings\/"},"modified":"2023-07-20T08:50:49","modified_gmt":"2023-07-20T12:50:49","slug":"clearside-biomedicals-suprachoroidal-injection-platform-to-be-featured-at-upcoming-asrs-and-ois-scientific-meetings","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/clearside-biomedicals-suprachoroidal-injection-platform-to-be-featured-at-upcoming-asrs-and-ois-scientific-meetings\/","title":{"rendered":"Clearside Biomedical\u2019s Suprachoroidal Injection Platform to be Featured at Upcoming ASRS and OIS Scientific Meetings"},"content":{"rendered":"<h2>\n&#8211; Presentations to Highlight CLS-AX as Promising Wet AMD Treatment with New Mechanism of Action and Potential for Longer Duration of Effect than Current Therapies &#8211;<br \/>\n<\/h2>\n<div class=\"mw_release\">\n<p align=\"justify\">ALPHARETTA, Ga., July  20, 2023  (GLOBE NEWSWIRE) &#8212; Clearside Biomedical, Inc.\u00a0(Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS<sup>\u00ae<\/sup>), announced today that presentations will be delivered at the American Society of Retina Specialists (ASRS) 41<sup>st<\/sup> Annual Scientific Meeting and the Ophthalmology Innovation Source (OIS) Retina Innovation Summit taking place July 27 \u2013 August 1, 2023 in Seattle, WA.<\/p>\n<p align=\"justify\">\n        <strong>Ophthalmology Innovation Source (OIS) Retina Innovation Summit <\/strong><br \/>\n        <br \/>Session: Spotlight on Drug Delivery<br \/>Moderator: Thomas A. Ciulla, M.D., MBA, Chief Medical Advisor-Retina and Chair, Scientific Advisory Board<br \/>Presenter: George Lasezkay, Pharm.D., J.D., President &amp; Chief Executive Officer<br \/>Date: Thursday, July 27, 2023<br \/>Time: 10:50 \u2013 11:50 am PT<\/p>\n<p align=\"justify\">\n        <strong>American Society of Retina Specialists (ASRS) <\/strong><br \/>\n        <br \/>Session: Wet AMD Symposium 2<br \/>Title: Safety and Tolerability of Suprachoroidal Injection of CLS-AX in Neovascular AMD Patients With Persistent Activity After Anti-VEGF Therapy<br \/>Presenter: Rahul N. Khurana, MD, FASRS<br \/>Date: Sunday, July 30, 2023<br \/>Time: 8:37 am PT<\/p>\n<p align=\"justify\">\n        <strong>About CLS-AX (axitinib injectable suspension)<\/strong>\n      <\/p>\n<p align=\"justify\">CLS-AX (axitinib injectable suspension) is a proprietary suspension of axitinib for suprachoroidal injection. Axitinib is a tyrosine kinase inhibitor (TKI), currently approved as an oral tablet formulation to treat advanced renal cell carcinoma, that achieves pan-VEGF blockade, directly inhibiting VEGF receptors-1, -2, and -3 with high potency and specificity. Clearside believes this broad VEGF blockade may have efficacy advantages over existing retinal therapies by acting at a different level of the angiogenesis cascade and may benefit patients who sub-optimally respond to current, more narrowly focused anti-VEGF therapies. Suprachoroidal injection of this proprietary suspension of axitinib has demonstrated meaningful potential in preclinical studies in multiple species and in a Phase 1\/2a wet AMD clinical trial in which CLS-AX was well tolerated and demonstrated an excellent safety profile. With suprachoroidal administration of axitinib, there is the potential to achieve prolonged duration and targeted delivery to affected tissue layers while limiting drug exposure to the front of the eye. Clearside is developing CLS-AX as a long-acting therapy for the treatment of retinal diseases.<\/p>\n<p align=\"justify\">\n        <strong>About Clearside\u2019s Suprachoroidal Space (SCS<\/strong><br \/>\n        <sup><br \/>\n          <strong>\u00ae<\/strong><br \/>\n        <\/sup><br \/>\n        <strong>) Injection Platform and SCS Microinjector<\/strong><br \/>\n        <sup><br \/>\n          <strong>\u00ae<\/strong><br \/>\n        <\/sup>\n      <\/p>\n<p align=\"justify\">Clearside\u2019s patent protected, proprietary suprachoroidal space (SCS<sup>\u00ae<\/sup>) injection treatment approach offers unprecedented access to the back of the eye, where sight-threatening disease often occurs. The Company\u2019s unique platform is inherently flexible and intended to work with established and new formulations of medications. Clearside\u2019s patented SCS Microinjector<sup>\u00ae<\/sup>\u00a0can deliver a wide variety of drug candidates into the suprachoroidal space, providing targeted delivery to potentially improve efficacy and compartmentalization of medication to reduce or eliminate toxic effects on non-diseased cells. The SCS Microinjector system comprises a syringe, a custom-designed hub, and two 30-gauge hollow microneedles of varying lengths, each less than 1.2 millimeters, optimizing insertion and suprachoroidal administration of drugs.<\/p>\n<p align=\"justify\">\n        <strong>About Clearside Biomedical, Inc.<\/strong>\n      <\/p>\n<p align=\"justify\">Clearside Biomedical, Inc. is a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS<sup>\u00ae<\/sup>). Clearside\u2019s SCS injection platform, utilizing the Company\u2019s patented SCS Microinjector<sup>\u00ae<\/sup>, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina, or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases. Clearside is developing its own pipeline of small molecule product candidates for administration via its SCS Microinjector. The Company\u2019s lead program, CLS-AX (axitinib injectable suspension), for the treatment of neovascular age-related macular degeneration (wet AMD), is in Phase 2b clinical testing. Clearside developed and gained approval for its first product, <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=J-AGmrPFNEKMthxe38dv16E5zqrHMK509n8ONR4AuYQ5_B9vGS6BU_3z7z8-3kJD0ZC13dlEYgOyaokW_6CF4utZw3C24_aGC8IZ8FEqWZedNbDlapdmUkKszNl-bXJXvmc7GA3UM-kGBo-7uAsuKJVDH3t1cthfI-hCsiaj3gI=\" rel=\"nofollow noopener\" target=\"_blank\">XIPERE\u00ae (triamcinolone acetonide injectable suspension)<\/a> for suprachoroidal use, which is available in the U.S. through a commercial partner. Clearside also strategically partners its SCS injection platform with companies utilizing other ophthalmic therapeutic innovations. For more information, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ES0HIxJ_CApz8bJCqf29o6RaKorG8wKwGtwLl3EaMKYm6BF7ouS9DcXgZaWECSWjW9q8XXgxvnDwX6L1bBH3ga1VByhK9QszJR8mZJaNgMQ=\" rel=\"nofollow noopener\" target=\"_blank\">clearsidebio.com<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>Forward-Looking Statements<\/strong>\n      <\/p>\n<p align=\"justify\">Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as \u201cbelieve\u201d, \u201cexpect\u201d, \u201cmay\u201d, \u201cplan\u201d, \u201cpotential\u201d, \u201cwill\u201d, and similar expressions, and are based on Clearside\u2019s current beliefs and expectations. These forward-looking statements include statements regarding the clinical development, and the potential benefits, of CLS-AX and therapies using Clearside\u2019s SCS Microinjector<sup>\u00ae<\/sup>. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include uncertainties inherent in the conduct of clinical trials, Clearside\u2019s reliance on third parties over which it may not always have full control and other risks and uncertainties that are described in Clearside\u2019s Annual Report on Form 10-K for the year ended December 31, 2022, filed with the U.S. Securities and Exchange Commission (SEC) on March 14, 2023 and Clearside\u2019s other Periodic Reports filed with the SEC. Any forward-looking statements speak only as of the date of this press release and are based on information available to Clearside as of the date of this release, and Clearside assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.<\/p>\n<p>\n        <strong>Investor and Media Contacts:<\/strong><br \/>\n        \n      <\/p>\n<p>Jenny Kobin <br \/>Remy Bernarda <br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=swCQ0HcxVgmtbcvUpe_yQIo7RtfX0Yz8RH_ed1cN2tyjfd92qU4UbX0G3Z3wzAdY61rh3Cj3jUEbgwwTFfm2WYxTBl5Cl8UYa6XZ0Ge-zog=\" rel=\"nofollow noopener\" target=\"_blank\">ir@clearsidebio.com<\/a><br \/>(678) 430-8206<\/p>\n<p>Source: Clearside Biomedical, Inc.<\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg3Nzc1MyM1NzAxMDc1IzIwMTExNjI=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/ODM2ZTNkMTQtM2M1Yi00ZjFmLWE4OTgtZmFhMTJjYTZmMmQyLTEwMjI3MzU=\/tiny\/Clearside-Biomedical-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>&#8211; Presentations to Highlight CLS-AX as Promising Wet AMD Treatment with New Mechanism of Action and Potential for Longer Duration of Effect than Current Therapies &#8211; ALPHARETTA, Ga., July 20, 2023 (GLOBE NEWSWIRE) &#8212; Clearside Biomedical, Inc.\u00a0(Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS\u00ae), announced today that presentations will be delivered at the American Society of Retina Specialists (ASRS) 41st Annual Scientific Meeting and the Ophthalmology Innovation Source (OIS) Retina Innovation Summit taking place July 27 \u2013 August 1, 2023 in Seattle, WA. Ophthalmology Innovation Source (OIS) Retina Innovation Summit Session: Spotlight on Drug DeliveryModerator: Thomas A. Ciulla, M.D., MBA, Chief Medical Advisor-Retina and Chair, Scientific Advisory &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/clearside-biomedicals-suprachoroidal-injection-platform-to-be-featured-at-upcoming-asrs-and-ois-scientific-meetings\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Clearside Biomedical\u2019s Suprachoroidal Injection Platform to be Featured at Upcoming ASRS and OIS Scientific Meetings&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-771222","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Clearside Biomedical\u2019s Suprachoroidal Injection Platform to be Featured at Upcoming ASRS and OIS Scientific Meetings - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/clearside-biomedicals-suprachoroidal-injection-platform-to-be-featured-at-upcoming-asrs-and-ois-scientific-meetings\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Clearside Biomedical\u2019s Suprachoroidal Injection Platform to be Featured at Upcoming ASRS and OIS Scientific Meetings - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"&#8211; Presentations to Highlight CLS-AX as Promising Wet AMD Treatment with New Mechanism of Action and Potential for Longer Duration of Effect than Current Therapies &#8211; ALPHARETTA, Ga., July 20, 2023 (GLOBE NEWSWIRE) &#8212; Clearside Biomedical, Inc.\u00a0(Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS\u00ae), announced today that presentations will be delivered at the American Society of Retina Specialists (ASRS) 41st Annual Scientific Meeting and the Ophthalmology Innovation Source (OIS) Retina Innovation Summit taking place July 27 \u2013 August 1, 2023 in Seattle, WA. Ophthalmology Innovation Source (OIS) Retina Innovation Summit Session: Spotlight on Drug DeliveryModerator: Thomas A. Ciulla, M.D., MBA, Chief Medical Advisor-Retina and Chair, Scientific Advisory &hellip; Continue reading &quot;Clearside Biomedical\u2019s Suprachoroidal Injection Platform to be Featured at Upcoming ASRS and OIS Scientific Meetings&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/clearside-biomedicals-suprachoroidal-injection-platform-to-be-featured-at-upcoming-asrs-and-ois-scientific-meetings\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-07-20T12:50:49+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg3Nzc1MyM1NzAxMDc1IzIwMTExNjI=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/clearside-biomedicals-suprachoroidal-injection-platform-to-be-featured-at-upcoming-asrs-and-ois-scientific-meetings\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/clearside-biomedicals-suprachoroidal-injection-platform-to-be-featured-at-upcoming-asrs-and-ois-scientific-meetings\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Clearside Biomedical\u2019s Suprachoroidal Injection Platform to be Featured at Upcoming ASRS and OIS Scientific Meetings\",\"datePublished\":\"2023-07-20T12:50:49+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/clearside-biomedicals-suprachoroidal-injection-platform-to-be-featured-at-upcoming-asrs-and-ois-scientific-meetings\\\/\"},\"wordCount\":901,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/clearside-biomedicals-suprachoroidal-injection-platform-to-be-featured-at-upcoming-asrs-and-ois-scientific-meetings\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODg3Nzc1MyM1NzAxMDc1IzIwMTExNjI=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/clearside-biomedicals-suprachoroidal-injection-platform-to-be-featured-at-upcoming-asrs-and-ois-scientific-meetings\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/clearside-biomedicals-suprachoroidal-injection-platform-to-be-featured-at-upcoming-asrs-and-ois-scientific-meetings\\\/\",\"name\":\"Clearside Biomedical\u2019s Suprachoroidal Injection Platform to be Featured at Upcoming ASRS and OIS Scientific Meetings - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/clearside-biomedicals-suprachoroidal-injection-platform-to-be-featured-at-upcoming-asrs-and-ois-scientific-meetings\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/clearside-biomedicals-suprachoroidal-injection-platform-to-be-featured-at-upcoming-asrs-and-ois-scientific-meetings\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODg3Nzc1MyM1NzAxMDc1IzIwMTExNjI=\",\"datePublished\":\"2023-07-20T12:50:49+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/clearside-biomedicals-suprachoroidal-injection-platform-to-be-featured-at-upcoming-asrs-and-ois-scientific-meetings\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/clearside-biomedicals-suprachoroidal-injection-platform-to-be-featured-at-upcoming-asrs-and-ois-scientific-meetings\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/clearside-biomedicals-suprachoroidal-injection-platform-to-be-featured-at-upcoming-asrs-and-ois-scientific-meetings\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODg3Nzc1MyM1NzAxMDc1IzIwMTExNjI=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODg3Nzc1MyM1NzAxMDc1IzIwMTExNjI=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/clearside-biomedicals-suprachoroidal-injection-platform-to-be-featured-at-upcoming-asrs-and-ois-scientific-meetings\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Clearside Biomedical\u2019s Suprachoroidal Injection Platform to be Featured at Upcoming ASRS and OIS Scientific Meetings\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Clearside Biomedical\u2019s Suprachoroidal Injection Platform to be Featured at Upcoming ASRS and OIS Scientific Meetings - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/clearside-biomedicals-suprachoroidal-injection-platform-to-be-featured-at-upcoming-asrs-and-ois-scientific-meetings\/","og_locale":"en_US","og_type":"article","og_title":"Clearside Biomedical\u2019s Suprachoroidal Injection Platform to be Featured at Upcoming ASRS and OIS Scientific Meetings - Market Newsdesk","og_description":"&#8211; Presentations to Highlight CLS-AX as Promising Wet AMD Treatment with New Mechanism of Action and Potential for Longer Duration of Effect than Current Therapies &#8211; ALPHARETTA, Ga., July 20, 2023 (GLOBE NEWSWIRE) &#8212; Clearside Biomedical, Inc.\u00a0(Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS\u00ae), announced today that presentations will be delivered at the American Society of Retina Specialists (ASRS) 41st Annual Scientific Meeting and the Ophthalmology Innovation Source (OIS) Retina Innovation Summit taking place July 27 \u2013 August 1, 2023 in Seattle, WA. Ophthalmology Innovation Source (OIS) Retina Innovation Summit Session: Spotlight on Drug DeliveryModerator: Thomas A. Ciulla, M.D., MBA, Chief Medical Advisor-Retina and Chair, Scientific Advisory &hellip; Continue reading \"Clearside Biomedical\u2019s Suprachoroidal Injection Platform to be Featured at Upcoming ASRS and OIS Scientific Meetings\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/clearside-biomedicals-suprachoroidal-injection-platform-to-be-featured-at-upcoming-asrs-and-ois-scientific-meetings\/","og_site_name":"Market Newsdesk","article_published_time":"2023-07-20T12:50:49+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg3Nzc1MyM1NzAxMDc1IzIwMTExNjI=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/clearside-biomedicals-suprachoroidal-injection-platform-to-be-featured-at-upcoming-asrs-and-ois-scientific-meetings\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/clearside-biomedicals-suprachoroidal-injection-platform-to-be-featured-at-upcoming-asrs-and-ois-scientific-meetings\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Clearside Biomedical\u2019s Suprachoroidal Injection Platform to be Featured at Upcoming ASRS and OIS Scientific Meetings","datePublished":"2023-07-20T12:50:49+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/clearside-biomedicals-suprachoroidal-injection-platform-to-be-featured-at-upcoming-asrs-and-ois-scientific-meetings\/"},"wordCount":901,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/clearside-biomedicals-suprachoroidal-injection-platform-to-be-featured-at-upcoming-asrs-and-ois-scientific-meetings\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg3Nzc1MyM1NzAxMDc1IzIwMTExNjI=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/clearside-biomedicals-suprachoroidal-injection-platform-to-be-featured-at-upcoming-asrs-and-ois-scientific-meetings\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/clearside-biomedicals-suprachoroidal-injection-platform-to-be-featured-at-upcoming-asrs-and-ois-scientific-meetings\/","name":"Clearside Biomedical\u2019s Suprachoroidal Injection Platform to be Featured at Upcoming ASRS and OIS Scientific Meetings - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/clearside-biomedicals-suprachoroidal-injection-platform-to-be-featured-at-upcoming-asrs-and-ois-scientific-meetings\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/clearside-biomedicals-suprachoroidal-injection-platform-to-be-featured-at-upcoming-asrs-and-ois-scientific-meetings\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg3Nzc1MyM1NzAxMDc1IzIwMTExNjI=","datePublished":"2023-07-20T12:50:49+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/clearside-biomedicals-suprachoroidal-injection-platform-to-be-featured-at-upcoming-asrs-and-ois-scientific-meetings\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/clearside-biomedicals-suprachoroidal-injection-platform-to-be-featured-at-upcoming-asrs-and-ois-scientific-meetings\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/clearside-biomedicals-suprachoroidal-injection-platform-to-be-featured-at-upcoming-asrs-and-ois-scientific-meetings\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg3Nzc1MyM1NzAxMDc1IzIwMTExNjI=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg3Nzc1MyM1NzAxMDc1IzIwMTExNjI="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/clearside-biomedicals-suprachoroidal-injection-platform-to-be-featured-at-upcoming-asrs-and-ois-scientific-meetings\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Clearside Biomedical\u2019s Suprachoroidal Injection Platform to be Featured at Upcoming ASRS and OIS Scientific Meetings"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/771222","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=771222"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/771222\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=771222"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=771222"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=771222"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}